Apr 28, 2026 08:32AM Quoin Pharmaceuticals plans investigator-led studies for QRX009

Mar 11, 2026 08:30AM Quoin Pharmaceuticals receives FDA fast track designation for QRX003

Jan 27, 2026 08:31AM Quoin seeks orphan drug status for QRX003 in Japan

Nov 11, 2025 08:31AM Quoin Pharmaceuticals achieves rapamycin loading targets for topical drugs

Oct 28, 2025 08:31AM Quoin Pharmaceuticals enrolls three patients in Netherton Syndrome study

Oct 21, 2025 08:30AM FDA grants orphan drug designation to Quoin's QRX003 for Netherton Syndrome

Aug 7, 2025 09:40AM Quoin Pharmaceuticals Ltd (QNRX) Misses Q2 EPS by 628c

Jul 29, 2025 08:30AM QNRX advances Netherton Syndrome drug in two pivotal studies

Jun 24, 2025 08:34AM Quoin Pharmaceuticals Ltd (QNRX) Granted FDA Rare Pediatric Disease Designation for QRX003

May 22, 2025 07:31AM Quoin Pharmaceuticals Ltd (QNRX) Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study

May 14, 2025 07:30AM Quoin Pharmaceuticals (QNRX) Announces Initial Positive Clinical Data for QRX003

Apr 30, 2025 07:31AM Quoin Pharmaceuticals (QNRX) Regains Compliance with Nasdaq Minimum Bid Price Rule

Mar 25, 2025 07:31AM Quoin Pharmaceuticals Ltd (QNRX) Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

Mar 4, 2025 07:30AM Quoin Pharmaceuticals (QNRX) Files U.S. and International Patent Applications for Novel Topical Rapamycin Formulations to Treat Rare Disease Indications

Feb 27, 2025 07:31AM Quoin Pharmaceuticals (QNRX) Announces Highly Positive ‘Whole Body’ Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Jan 23, 2025 05:30AM Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Jan 14, 2025 08:34AM Quoin Pharmaceuticals (QNRX) Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Jan 6, 2025 08:33AM Quoin Pharmaceuticals (QNRX) Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

Dec 20, 2024 09:20AM Quoin Pharmaceuticals (QNRX) Announces Pricing of $6.8 Million Public Offering

Dec 18, 2024 08:18AM Quoin Pharmaceuticals Ltd (QNRX) Reports Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

Nov 5, 2024 08:02AM Quoin Pharmaceuticals (QNRX) Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome Patient

Oct 22, 2024 08:01AM Quoin Pharmaceuticals Ltd (QNRX) Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome

Sep 9, 2024 08:33AM Quoin Pharmaceuticals Ltd (QNRX) Announces Insider Share Purchases by Co-Founders CEO and COO

Jun 12, 2024 08:14AM Quoin Pharmaceuticals (QNRX) Announces Signing of Research Agreement with University College Cork, Ireland